The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it. Despite an approach to developing antibodies and other biologics that looks decidedly different--they're developed from spirulina cell lines and, in some cases, designed for oral administration (gasp!)--Lumen Biosciences has won hard-fought funding from some nontraditional sources to continue its mission to democratize biologics. Finrow is Co-Founder & CEO at Lumen, and now a two-time guest of the Business of Biotech. He's a Harvard J.D., but don't hold that against him. He's one of the most approachable and transparent founders we've enjoyed the pleasure of hosting, and he didn't disappoint when we sat down for this talk in San Francisco.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Kapitel

1. The Business of Biotech Update (00:00:00)

2. Changing Trends in Biotech Funding (00:05:16)

3. Regulatory & Conceptual Landscape of Biotechnology (00:19:06)

4. R&D Productivity and Drug Development Challenges (00:24:38)

5. Considering AI in Drug Development (00:33:01)

6. Embracing Serendipity in Business (00:44:25)